Abstract:Background: As the most common primary malignant bone tumor in children and adolescents, osteosarcoma currently lacks an effective clinical cure. Focal adhesion plays a crucial role in tumor invasion, migration, and drug resistance by mediating communication between the extracellular matrix and tumor cells. This study investigated the prognostic features and immunotherapeutic relevance of focal adhesion pathway-related genes in osteosarcoma to aid in the development of new therapeutic options. Methods: We obtained mutational, transcriptomic, gene expression, and clinical data of osteosarcoma patients from the Gene Expression Omnibus (GEO) and Therapeutically Applicable Research to Generate Effective (TARGET) databases. Differentially expressed genes were screened, followed by the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. Kaplan-Meier survival analysis was performed for genes related to the focal adhesion pathway, and multivariate Cox regression analysis was employed to construct a prognostic signature model. Genes such as SIGLEC15, TIGIT, CD274, HAVCR2, PDCD1, CTLA4, and LAG3 were extracted from the TARGET and CCLE databases for osteosarcoma patients and osteosarcoma cell lines, respectively，to observe the expression of immune checkpoint-related genes. Finally, qRT-PCR was used to verify the expression of these immune checkpoint-related genes in osteosarcoma cell lines. Results: In our study, 376 samples were analyzed, including 369 osteosarcoma samples and 7 normal tissue samples. We identified 50 up-regulated and 28 down-regulated differentially expressed genes. Among these, 10 Candidate genes relative to focal Adhesion were selected， and CAV1, ZYX, and ITGA5 were found to have a significant prognostic role based on survival analysis of osteosarcoma samples from the TARGET database. A predictive signature model related to the focal adhesion signaling pathway was constructed using these genes, and the AUCs of the 1-year, 3-year, and 5-year ROC curves were 0. 647, 0. 712, and 0. 717, respectively. The overall survival (OS) rate of osteosarcoma patients with high-risk scores was poorer than those with low-risk scores. Then, samples were divided into two subgroups based on the expression of the three genes, revealing significant differences in the expression of certain immune checkpoint-related genes between the subgroups. Additionally, above three genes and immune checkpoint-related genes in osteosarcoma cell lines were extracted from the CCLE database, showing high expression levels in eight osteosarcoma cell lines. We observed that CD274 and PDCD1LG2 were highly expressed in some osteosarcoma cell lines. Finally, the expression of CAV1, ZYX, ITGA5, CD80, CD274, and PDCD1LG2 in osteosarcoma cell lines was verified by qRT-PCR. Conclusions: Our study validated the prognostic role of three focal adhesion pathway-related genes (ZYX, CAV1, and ITGA5) in patients with osteosarcoma and constructed a prognostic signature model associated with the focal adhesion signaling pathway. We identified significant differences in the expression of multiple immune checkpoint-related genes among subgroups defined by the three genes. Additionally, CD274 and PDCD1LG2 showed higher expression in osteosarcoma cell lines characterized by these genes. These findings may aid in the selection of effective immunotherapy for specific osteosarcoma patients.

URG4 Mediates Cell Proliferation and Cell Cycle in Osteosarcoma Via GSK3β/β-catenin/cyclin D1 Signaling Pathway

The expression of novel gene URG4 in osteosarcoma: correlation with patients' prognosis.

TBRG4 Knockdown Suppresses Proliferation and Growth of Human Osteosarcoma Cell Lines MG63 Through PI3K/Akt Pathway

Downregulation of B4GALNT1 inhibits proliferation and metastasis of osteosarcoma cells

Endothelial Cells Promote Osteosarcoma Cell Metastasis by Inhibiting LGI4 Expression and Activating NOTCH4 Signaling Pathway

Osteoblast-derived exosomes promote osteogenic differentiation of osteosarcoma cells via URG4/Wnt signaling pathway

WITHDRAWN: PADI4 Regulates Osteosarcoma Proliferation Primarily Via Wnt/β-catenin and MEK/ERK Signaling Pathway

DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo

CUL4B Promotes Proliferation and Inhibits Apoptosis of Human Osteosarcoma Cells.

Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4

MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma

HER4 Promotes the Growth and Metastasis of Osteosarcoma Via the PI3K/AKT Pathway.

KLF4 Functions As an Oncogene in Promoting Cancer Stem Cell-Like Characteristics in Osteosarcoma Cells

ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway

Long Non-Coding RNA Sox4 Promotes Proliferation and Migration by Activating Wnt/β-catenin Signaling Pathway in Osteosarcoma.

Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation

Prognostic Signature and Immunotherapeutic Relevance of Focal Adhesion Signaling Pathway-Related Genes in Osteosarcoma

Glycogen Synthase Kinase-3β, NF-κB Signaling, and Tumorigenesis of Human Osteosarcoma

Heterogeneous Expression and Biological Function of Ubiquitin Carboxy-Terminal Hydrolase-L1 in Osteosarcoma

Promotion of Proliferation and Inhibition of Apoptosis by Diacylglycerol Kinase Zeta, a Potential Oncogene of Osteosarcoma

HMGB1 Promotes Cellular Proliferation and Invasion, Suppresses Cellular Apoptosis in Osteosarcoma